Geron (GERN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 annual meeting: Susan M. Molineaux, Ph.D., Patricia S. Andrews, and Constantine Chinoporos.
Approval sought for an amendment and restatement of the 2018 Equity Incentive Plan, increasing available shares by 4,500,000 and making additional changes.
Advisory vote on the compensation of Named Executive Officers as disclosed in the proxy statement.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies authorized to vote on other matters that may arise during the meeting or any adjournments.
Board of directors and corporate governance
Three nominees are presented for election as Class III directors, each to serve a term ending at the 2029 annual meeting.
Executive compensation and say-on-pay
Advisory approval requested for the compensation of Named Executive Officers, as detailed in the proxy statement.
Latest events from Geron
- Imetelstat anchors second-line MDS therapy, with strong growth and pivotal myelofibrosis data ahead.GERN
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Virtual meeting to vote on directors, equity plan, executive pay, and auditor, with strong governance.GERN
Proxy filing7 Apr 2026 - RYTELO net revenue hit $184M in 2025, with 2026 guidance set at $220M-$240M and strong demand growth.GERN
Q4 20257 Apr 2026 - RYTELO drives robust growth with global expansion plans and pivotal MF trial data expected in 2026.GERN
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - RYTELO targets strong growth in 2025, supported by market trends, ISTs, and global expansion.GERN
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - RYTELO drives revenue growth and clinical leadership in LR-MDS, with expansion into new markets ahead.GERN
Corporate presentation25 Feb 2026 - FDA approval and U.S. launch of RYTELO drive early revenue and strong financial position.GERN
Q2 20242 Feb 2026 - FDA approves first telomerase inhibitor for transfusion-dependent low-risk MDS, enabling broad access.GERN
FDA Announcement1 Feb 2026 - RYTELO's Q3 launch drove $28.2M revenue and $375M in new capital, fueling future growth.GERN
Q3 202416 Jan 2026